# Ghrelin and Beta Cell Function in Diabetes

> **NCT02440061** · PHASE1 · WITHDRAWN · sponsor: **Jenny Tong, MD, MPH**

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Synthetic human AG
- **DRUG:** Arginine
- **DRUG:** 0.9% saline solution

## Key facts

- **NCT ID:** NCT02440061
- **Lead sponsor:** Jenny Tong, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-05
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This protocol was replaced with a different one and therefore discontinued.
- **Last updated:** 2018-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440061, "Ghrelin and Beta Cell Function in Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02440061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*